{"id":601166,"date":"2023-12-14T20:17:36","date_gmt":"2023-12-14T17:17:36","guid":{"rendered":"https:\/\/en.buradabiliyorum.com\/mitsubishi-tanabe-pharma-canadas-commitment-to-canadians-living-with-als\/"},"modified":"2023-12-14T20:17:36","modified_gmt":"2023-12-14T17:17:36","slug":"mitsubishi-tanabe-pharma-canadas-commitment-to-canadians-living-with-als","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/mitsubishi-tanabe-pharma-canadas-commitment-to-canadians-living-with-als\/","title":{"rendered":"#Mitsubishi Tanabe Pharma Canada\u2019s commitment to Canadians living with ALS\u00a0"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a38748eac8f9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #dd3333;color:#dd3333\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #dd3333;color:#dd3333\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a38748eac8f9\" checked aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/buradabiliyorum.com\/en\/mitsubishi-tanabe-pharma-canadas-commitment-to-canadians-living-with-als\/#Breaking_new_ground_in_ALS_research\" >Breaking new ground in ALS research<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/buradabiliyorum.com\/en\/mitsubishi-tanabe-pharma-canadas-commitment-to-canadians-living-with-als\/#Improving_early_detection_of_ALS\" >Improving early detection of ALS<\/a><\/li><\/ul><\/nav><\/div>\n<div>\n\u201c[We\u2019re] focused on areas that we believe will have the greatest impact for patients \u2013 both within and beyond medicine\u201d\n<\/div>\n<div>\nSince opening its doors in 2018, Mitsubishi Tanabe Pharma Canada (MTP-CA) has been on a relentless mission to make a difference in the lives of Canadians impacted by Amyotrophic Lateral Sclerosis (ALS)\u2014also known as Lou Gehrig\u2019s disease\u2014a fatal neurological disorder that causes progressive degeneration of nerve cells in the spinal cord and brain.<sup>i<\/sup><\/p>\n<p>A key milestone in the company\u2019s commitment to Canadians living with ALS was the 2018 Health Canada <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/download-scripts-themes-apps\/\" data-internallinksmanager029f6b8e52c=\"9\" title=\"Download Scripts &amp; Themes &amp; Apps\" target=\"_blank\" rel=\"noopener\">app<\/a>roval of the first new ALS treatment option in almost 20 years.<sup>ii<\/sup> For Mike Cels, who was diagnosed with ALS the year before, it was a significant moment for himself, his wife Carmen, his two kids and his family and friends.<\/p>\n<p>\u201cFor nearly 20 years, Canadians who live with ALS had only one treatment option available to them,\u201d recalls Carmen. \u201cWe were fortunate to have had an additional treatment option for Mike in 2018. And now, today, new treatment advances and ongoing ALS research to slow the progression of ALS are providing more much-needed hope to the ALS community.\u201d<\/p>\n<p>In 2022, following a Priority Review by Health Canada, MTP-CA introduced an oral suspension version of its drug that is formulated with the challenges of people living with ALS in mind.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Breaking_new_ground_in_ALS_research\"><\/span>Breaking new ground in ALS research<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Over the past five years, MTP-CA has invested heavily in research and development projects\u2014including forward-thinking health solutions so that patients may access therapies earlier on, collaborations with partners to generate real-world evidence and one-of-a-kind solutions to help advance the clinical practices of healthcare professionals.<\/p>\n<p>\u201cWe are honoured to have built close relationships with the ALS community as we worked to understand the unique unmet needs of Canadians impacted by the disease,\u201d said Andy Zylak, president, MTP-CA. \u201cToday, we are focused on areas that we believe will have the greatest impact for patients\u2014both within and beyond medicine.\u201d<\/p>\n<p>One of these areas is collecting real-world data on the treatment of ALS. The company recently announced its first-ever collaboration with the Canadian Neuromuscular Disease Registry (CNDR) at the\u202fUniversity of Calgary to study its treatment, in hopes of uncovering new insights that will benefit people living with ALS.<sup>iii<\/sup><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Improving_early_detection_of_ALS\"><\/span>Improving early detection of ALS<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>One of the greatest challenges in ALS is the long and complicated process of diagnosis. For some, it can take up to two years to receive a diagnosis of ALS in Canada, and the majority of people living with ALS die within three years of first symptom onset.<sup>iv<\/sup><\/p>\n<p>\u201cWe know that people with ALS do not have the luxury of time,\u201d said Dung Pham, Medical Affairs Director, Mitsubishi Tanabe Pharma Canada. \u201cWe are passionate about improving the time to diagnosis to ensure that all patients can access multidisciplinary care, approved medications and clinical trials that can potentially improve survival and enhance their quality of life.\u201d<\/p>\n<p>The company, supporting leading Canadian neurologists, recently announced its support of a ground-breaking artificial intelligence program, utilizing <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/technology\/\" data-internallinksmanager029f6b8e52c=\"4\" title=\"Technology\" target=\"_blank\" rel=\"noopener\">technology<\/a>* developed by Ensho Health to analyze de-identified electronic medical records \u00a0and identify individuals for which follow-up investigations for ALS or referral to a specialty centre may be clinically appropriate.<sup>v<\/sup><\/p>\n<p>\u201cWe are committed to tackling these challenges on behalf of the ALS community,\u201d added Zylak. \u201cAnd we will continue to fight alongside them, pursuing scientific innovation, reducing the time to diagnosis and improving access to new treatment options, now and into the future.\u201d<\/p>\n<p style=\"font-size: 11px;\">* The MNd-5 algorithm is a process for converting input parameters to a likelihood estimate. It is deployed at the Toronto, Canada data lab of Ensho Health through the MNd-5 CDL Module (\u201cCDL Module\u201d). The CDL Module is comprised of the MNd-5 Likelihood Estimator (\u201cLikelihood Estimator\u201d) which encodes it in software and a graphical user interface called the MNd-5 Controller (\u201cController\u201d). The CDL Module was developed to the ISO 13485:2016 standard for medical devices in compliance with Ensho\u2019s Quality Management System. The MNd-5 CDL Module is registered as medical device software in Canada under the Medical Device Establishment License of Ensho Health (license 16208). The software that encodes the MNd-5 algorithm and applies it to EHR data is Class I medical device software in Canada developed and deployed under the Medical Device Establishment License of Ensho Health.<\/p>\n<hr\/>\n<p style=\"font-size: 11px;\"><sup>i<\/sup> Cedars Sinai Health Library. What is ALS? Available at\u00a0: <a rel=\"nofollow noopener\" target=\"_blank\" href=\"https:\/\/sr.studiostack.com\/c\/link?l=1480141&amp;s=1480125\">https:\/\/www.cedars-sinai.org\/health-library\/diseases-and-conditions\/a\/amyotrophic-lateral-sclerosis-als.html<\/a>. Accessed on October 11, 2023<\/p>\n<p style=\"font-size: 11px;\"><sup>ii<\/sup> Health Canada Drug Database. Available at: <a rel=\"nofollow noopener\" target=\"_blank\" href=\"https:\/\/sr.studiostack.com\/c\/link?l=1480143&amp;s=1480125\">https:\/\/health-products.canada.ca\/dpd-bdpp\/<\/a> \u00a0Accessed on September 28, 2023.<\/p>\n<p style=\"font-size: 11px;\"><sup>iii<\/sup> Abrahao, A, Vyas, M, Parks, A, Hodgkinson, V, et al. Abstract: Real-World Survival Effectiveness of Edaravone in Amyotrophic Lateral Sclerosis: A Propensity Score Weighted, Registry-Based, Canada-Wide Cohort Study. Presented at the Canadian Neurological <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/sciencee\/\" data-internallinksmanager029f6b8e52c=\"5\" title=\"Science\" target=\"_blank\" rel=\"noopener\">Science<\/a>s Federation\u2019s Congress 2023.<\/p>\n<p style=\"font-size: 11px;\"><sup>iv<\/sup> Shoesmith C, Abrahao A, Benstead T, et al. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. CMAJ 2020;192:E1453-68.<\/p>\n<p style=\"font-size: 11px;\"><sup>v<\/sup> Process for Progress in ALS: An EMR-based practice enhancement initiative. Available at: <a rel=\"nofollow noopener\" target=\"_blank\" href=\"https:\/\/sr.studiostack.com\/c\/link?l=1480149&amp;s=1480125\">https:\/\/www.alsprogress.ca<\/a>. \u00a0Accessed on September 19, 2023.<\/p>\n<\/div>\n<p><script async defer crossorigin=\"anonymous\" src=\"https:\/\/connect.facebook.net\/en_US\/sdk.js\"><\/script><\/p>\n<blockquote><p><strong><span style=\"color: #ff6600;\">If you liked the article, do not forget to share it with your friends. Follow us on\u00a0<span style=\"color: #ff0000;\"><a style=\"color: #ff0000;\" href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMLG0nwswvr63Aw\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Google News<\/a><\/span>\u00a0too, click on the star and choose us from your favorites.<\/span><\/strong><\/p><\/blockquote>\n<blockquote>\n<p style=\"text-align: center;\">For forums sites go to <span style=\"color: #ff9900;\"><a style=\"color: #ff9900;\" href=\"https:\/\/forum.buradabiliyorum.com\/\" target=\"_blank\" rel=\"noopener\">Forum.BuradaBiliyorum.Com<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n<blockquote>\n<p style=\"text-align: center;\"><strong>If you want to read more <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/news\/\" data-internallinksmanager029f6b8e52c=\"2\" title=\"News\" target=\"_blank\" rel=\"noopener\">News<\/a> articles, you can visit our <span style=\"color: #ff9900;\"><a style=\"color: #ff9900;\" href=\"https:\/\/en.buradabiliyorum.com\/general\/\" target=\"_blank\" rel=\"noopener\">General category.<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n<p><span style=\"color: black;\"><a style=\"color: #ff9900;\" href=\"https:\/\/macleans.ca\/sponsored\/mitsubishi-tanabe-pharma-canadas-commitment-to-als\/\" target=\"_blank\" rel=\"noopener\">Source<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201c[We\u2019re] focused on areas that we believe will have the greatest impact for patients \u2013 both within and beyond medicine\u201d Since opening its doors in 2018, Mitsubishi Tanabe Pharma Canada (MTP-CA) has been on a relentless mission to make a difference in the lives of Canadians impacted by Amyotrophic Lateral Sclerosis (ALS)\u2014also known as Lou&#8230;<\/p>\n","protected":false},"author":1,"featured_media":601167,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/macleans.ca\/wp-content\/uploads\/2023\/12\/Mac-MTP-CA-F.jpg","fifu_image_alt":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-601166","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/601166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/comments?post=601166"}],"version-history":[{"count":0,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/601166\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media\/601167"}],"wp:attachment":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media?parent=601166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/categories?post=601166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/tags?post=601166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}